Home › Chronic Lymphocytic Leukemia › Louisiana › New Orleans
Chronic Lymphocytic Leukemia clinical trials in New Orleans, LA
3 studies for Chronic Lymphocytic Leukemia are looking for participants at sites in and around New Orleans (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- University Medical Center New Orleans, New Orleans
- Touro Infirmary, New Orleans
- West Jefferson Medical Center, Marrero · 4 mi away
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
RecruitingPhase 3
- Ochsner Clinic Foundation, New Orleans
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RecruitingPhase 3
- Ochsner Clinic Foundation, New Orleans
Chronic Lymphocytic Leukemia trials in other cities
- Boston, MA31 studies
- Columbus, OH28 studies
- Durham, NC27 studies
- Washington, DC22 studies
- Seattle, WA20 studies
- New York City, NY18 studies
- Rochester, MN18 studies
- Houston, TX17 studies
- Baldwin Park, CA16 studies
- Milwaukee, WI15 studies
- Chicago, IL14 studies
- Cincinnati, OH14 studies
Other studies in New Orleans
- Cancer (all types)12 studies
- Ovarian Cancer12 studies
- Breast Cancer11 studies
- Prostate Cancer10 studies
- Endometrial Cancer9 studies
- Metastatic Cancer9 studies
- Lung Cancer9 studies
- Non-Small Cell Lung Cancer9 studies
- Cardiovascular Disease9 studies
- Obesity8 studies
- Steatotic Liver Disease8 studies
- Colorectal Cancer8 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.